NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9).

Members Present: Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Tracy Klein, PhD, FNP; Caryn Mickelson, PharmD; Stacy Ramirez, PharmD; James Slater, PharmD; Cathy Zehrung, RPh

Members Present by Phone: Kelley Burnett, DO; Dave Pass, MD

Staff Present: Roger Citron, RPh; Sarah Servid, PharmD; David Engen, PharmD, CGP; Deanna Moretz, PharmD, BCPS; Kara Shirley, PharmD, BCACP, BCPS, BCPP; Richard Holsapple, RPh; Dee Weston; Jennifer Torkelson; Brandon Wells; Jonnaliz Corbett; Trevor Douglass, DC, MPH

Staff Present by Phone: Kathy Sentena, PharmD

Audience: Tim McFerron, Alkermes; *Paul Thompson, Alkermes; Georgette Dzwilewski, Indivior; Joelle Ayoub, OHSU; *Mark Kohn, Novo Nordisk; *Kyle Gunter, Paratek; Erick Shoffe, Paratek; Trey Davenhill, Oregon State University; Sean Privette, Pacific University; Lisa Boyle, WVP Health; Bobbi Jo Duim, BMS; Dana Sox, AMAG; *Lisa Wells, Greenwich Biosciences; Tracey Larrah, AMAG; Keri Smith, Viiv; Trent Taylor, J&J; *Stephanie Yamamoto, J&J; Doug Buriani, Sobi; Troy Pendergraft, Tandem Diabetes Care; Chris Tanaka, Dexcom; *Margaret Olmon, AbbVie; Jeana Colabianchi, Sunovion; Danielle Shannon, WVP Health; *Keith Cheng, MHCAG; *George Fussell, MHCAG; Heidi Memmott, Takeda; Laura Jeffcoat, AbbVie

*Provided public testimony

Written testimony provided: Posted to OSU Website
I.  CALL TO ORDER

A. The meeting was called to order at approximately 1:05 pm. Introductions were made by Committee members and staff.
B. No new conflicts of interest were declared.
C. Approval of agenda and January 2019 minutes presented by Mr. Citron.
   ACTION: Motion to approve, 2nd, all in favor
D. Department Update: Trevor Douglass reviewed staffing changes.
E. Legislative Update: Trevor Douglass reviewed agency policy during legislative session regarding discussion of active bills. Reviewed: HB2678, SB138, HB2692, HB3093, SB872, HB 2689, HB 2680, and HB 2679.

II. CONSENT AGENDA TOPICS

A. GLP-1 Receptor Agonists Literature Scan
   Recommendation:
   • Make no changes to the PMPDP based on clinical evidence.
   • Evaluate comparative drug costs in executive session.
   
   ACTION: Amended to reorganize questions to ask about concomitant insulin use in #6 of the criteria. Modified criteria to allow use of basal insulin when in combination with a GLP-1 and specifically allow auto-PA for patients with claims for metformin use in the previous 40 days.
   
   Motion to approve, 2nd, All in Favor

III. DUR ACTIVITIES

A. Quarterly Utilization Report – Mr. Citron presented the Quarterly Utilization Report
B. ProDUR Report – Mr. Holsapple presented the ProDUR Report
C. RetroDUR Report – Dr. Engen presented the RetroDUR Report
D. Oregon State Drug Reviews
   1. Updates on Testosterone Therapy
   2. Basal Insulin Update

   Dr. Sentena presented two recently published newsletters, thanked the Committee for reviewing the draft versions and solicited ideas for future newsletters.

IV. DUR OLD BUSINESS

A. Calcium/Vitamin D Prior Authorization Update

   Dr. Sentena presented the proposal to:
   • Add a vitamin D solution suitable for infants to the Practitioner-Managed Prescription Drug Plan (PMPDP)
   • Evaluate comparative costs in executive session.

   ACTION: Motion to approve, 2nd, all in favor
B. Hydroxyprogesterone Prior Authorization Update
Dr. Servid presented the proposal to:
   • Update PA criteria to accommodate new generics for Makena®.

ACTION: Motion to approve, 2nd, all in favor

C. Benzodiazepine Prior Authorization Update
Dr. Servid presented the proposal to:
   • Update PA criteria to include outpatient management of alcohol withdrawal syndrome.

ACTION: Amended to add prescribing specialists in mental health to questions #9 and #11.

Motion to approve, 2nd, all in favor

D. Cannabidiol Prior Authorization Update
Dr. Moretz presented the proposal to:
   • Update PA criteria to include maximum dose limits.

ACTION: Motion to approve, 2nd, all in favor

V. PREFERRED DRUG LIST NEW BUSINESS

A. Tetracycline Class Update and New Drug Evaluation
Dr. Sentena presented the proposal to:
   • Make no changes to the PMPDP based on clinical evidence.
   • Evaluate comparative drug costs in executive session.

ACTION: Motion to approve, 2nd, all in favor

B. Hereditary Angioedema Agents Class Review
Dr. Servid presented the proposal to:
   • Implement PA criteria to promote use for appropriate indications and ensure safe use.
   • Make ecallantide non-preferred due to concerns with anaphylaxis.
   • Evaluate comparative costs in executive session.

ACTION: amend proposed PA criteria to require laboratory documentation of diagnosis, add dosing table, and move question regarding preferred/nonpreferred drugs to later in PA after all clinical criteria are met.

Motion to approve, 2nd, all in favor

C. Endometriosis Class Review
Dr. Moretz presented the proposal to:
• Combine PA criteria for GnRH analogs and antagonists into one criteria entitled GnRH Modifiers and retire previous criteria.
• Revise step therapy for elagolix to remove requirement for trial of acetaminophen or a nonsteroidal anti-inflammatory agent.
• Add endometriosis diagnosis with step therapy for leuprolide, goserelin, and nafarelin.
• Reinforce warnings about bone mineral density (BMD) loss with use of GnRH modifiers.
• Evaluate comparative costs of GNRH analogs and antagonists in executive session

ACTION: Amended to limit approval to the FDA approved duration for GnRH analogues

Motion to approve, 2nd, all in favor

VI. DUR NEW BUSINESS

A. Mental Health Clinical Advisory Group
Ms. Parish provided some background on the work of the MHCAG and announced that the schizophrenia algorithm that was developed was published today.

Drs. Fussell and Cheng shared the process employed in the development of the algorithm, the hope that it will be a useful tool to the state. There was also discussion about the bipolar algorithm that they are next developing.

B. Antipsychotics for Schizophrenia Drug Use Evaluation & Literature Scan
Drs. Moretz and Servid presented the proposal to:
• Make no changes to the PMPDP for oral or parenteral antipsychotics based on clinical evidence.
• Continue to explore opportunities for provider education and retrospective DUR initiatives.
• Evaluate costs in executive session.

ACTION: Motion to approve, 2nd, all in favor

VII. EXECUTIVE SESSION

Members Present: Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Tracy Klein, PhD, FNP; Caryn Mickelson, PharmD; Stacy Ramirez, PharmD; James Slater, PharmD; Cathy Zehrung, RPh

Members Present by Phone: Kelley Burnett, DO; Dave Pass, MD

Staff Present: Roger Citron, RPh; Sarah Servid, PharmD; David Engen, PharmD, CGP; Deanna Moretz, PharmD, BCPS; Kara Shirley, PharmD, BCACP, BCPS, BCPP; Richard Holsapple, RPh Dee Weston; Jennifer Torkelson; Brandon Wells; Jonnaliz Corbett; Trevor Douglass, DC, MPH
VIII. RECONVENE FOR PUBLIC RECOMMENDATIONS * After executive session

A. GLP-1 Receptor Agonists Literature Scan
   Recommendation: Add exenatide vials (Bydureon) and liraglutide (Victoza 2 and 3 Pak) to the PDL. Allow auto PA of preferred therapies if patient has a history of metformin use (previous or current)
   ACTION: Motion to approve items, 2nd, majority in favor with one opposed

B. Calcium/Vitamin D Prior Authorization Update
   Recommendation: Make cholecalciferol (vitamin D3) (Baby Ddrops) preferred on the PMPDP
   ACTION: Motion to approve items, 2nd, all in favor

C. Tetracycline Class Update and New Drug Evaluation
   Recommendation: no changes to the PMPDP
   ACTION: Motion to approve items, 2nd, all in favor

D. Hereditary Angioedema Agents Class Review
   Recommendation: Make C1 esterase inhibitor (Berinert®) and C1 esterase inhibitor (Haegarda®) preferred on the PMPDP
   ACTION: Motion to approve items, 2nd, all in favor

E. Endometriosis Class Review
   Recommendation: no changes to the PMPDP
   ACTION: Motion to approve items, 2nd, all in favor

F. Antipsychotics Literature Scan
   Recommendation: no changes to the PMPDP
   ACTION: Motion to approve items, 2nd, all in favor

IX. ADJOURN